Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, emphasize the importance of shared decision-making, comprehensive data, and well-informed multidisciplinary team collaboration in delivering high-quality, patient-centered care, while highlighting the benefits of tailored adjuvant therapies.
Medical professionals discuss proactive symptom management for adverse events like diarrhea, hair thinning, cytopenia, and neutropenia, offering guidance on dose reduction and treatment holds to optimize patient outcomes while minimizing adverse effects.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.
Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, discuss the biological and pathological risk factors influencing breast cancer development, treatment, and risk stratification.
provides hope for breast cancer patients. in an early krin i canal trial, researchers say an spermal drug helped advanced stage breast cancer from advancing or getting worse. joining us is senior managing editor of fox health.com. how impressive are the results of this trial, a small trial? >> it is small but impressive. what you're looking at is a drug that has prolonged the worsening, if you will, of advanced metastatic cancer by 20 months compared to, let's say, a control of 10 months. so when you look at that doubling, and there was earlier reports when the medication came out that it was even better, you know, the numbers were even higher statistically so everybody got very excited. you know, that's -- and the numbers are going to be very good for patients and i think that this drug works in a very unique way. it works by really not allowing